Merck eyes growth beyond Keytruda with PAH drug Winrevair, aiming to offset the looming loss of exclusivity in 2028.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

Merck's heavy reliance on Keytruda continues to grow, with the drug nearing 50% of total sales and limited growth from other ...

Pharmaceutical companies are heading toward a steep patent cliff that could strip more than $230 billion in US drug sales ...

Summit Therapeutics' potential pipeline could help drive strong stock performances for a long time. Is it worth it to buy a ...

Recent FDA decisions added new options for dermatologists involved in treating patients with psoriasis, bullous pemphigoid ...

The approval comes amid speculation that AstraZeneca CEO Pascal Soriot is considering delisting its UK stock market listing for the US.

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

Breaking down what patients should know about each FDA therapeutic approval from June 2025 across various oncology ...

Serendipity Space, a pioneering space-tech company developing microgravity-based pharmaceutical manufacturing solutions, has raised its pre-seed round from Campus Fund. The investment will accelerate ...

Novo Nordisk NVO has experienced remarkable growth in recent years, largely fueled by the commercial success of its ...